Keyphrases
Acute Exacerbation of COPD (AECOPD)
23%
Admission Rate
17%
All-cause Mortality
15%
Antibiotic Treatment
11%
Antibiotics
16%
Antibody Response
8%
Arterial Hypertension
14%
Asthma
37%
Asthma Exacerbation
17%
Azithromycin
17%
BNT162b2
8%
Bronchiectasis
17%
Calcium Channel Blockers
8%
Cardiovascular Events
8%
Chronic Obstructive Pulmonary Disease
81%
Chronic Obstructive Pulmonary Disease Patient
28%
Chronic Pulmonary Disease
8%
Community-acquired Pneumonia
10%
Confidence Interval
9%
Corticosteroids
11%
COVID-19
10%
COVID-19 Mortality
8%
COVID-19 Risk
8%
COVID-19 Vaccination
8%
Denmark
17%
Exacerbation Rate
17%
Genetic Analysis
8%
Hazard Ratio
22%
High Risk
12%
Hospitalization
39%
Hospitalization Risk
11%
Immunological Outcomes
8%
Inhaled Corticosteroid Therapy
9%
Inhaled Corticosteroids
51%
Low Responder
8%
Montelukast
8%
National Cohort Study
48%
National Lockdown
10%
Neuropsychiatric Adverse Events
13%
New Onset
8%
Oral Corticosteroids
20%
Pneumonia
15%
Psychiatric Symptoms
8%
Retrospective Cohort Study
8%
Severe Chronic Obstructive Pulmonary Disease
20%
Social Distancing
23%
Social Distancing Measures
21%
Systemic Corticosteroids
21%
Venous Thromboembolism
17%
Very Severe
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
All Cause Mortality
12%
Amlodipine
8%
Amoxicillin
8%
Antibiotic Agent
12%
Antibiotics
17%
Antidepressant
16%
Anxiety Disorder
5%
Asthma
14%
Azithromycin
17%
Bendroflumethiazide
5%
Bipolar Disorder
5%
Calcium Channel Blocker
8%
Chronic Obstructive Lung Disease
100%
Clarithromycin
8%
Cohort Study
35%
Coronavirinae
8%
Corticosteroid
23%
Depression
8%
Disease
10%
Ethanol
8%
Hydroxychloroquine
8%
Hypertension
14%
Inhalation Device
8%
Lung Disease
8%
Macrolide
8%
Malignant Neoplasm
5%
Montelukast
8%
Muscarinic Receptor Blocking Agent
8%
Placebo
8%
Pseudomonas aeruginosa
8%
Pseudomonas Infection
8%
Psoriasis
8%
Randomized Clinical Trial
8%
Randomized Controlled Trial
8%
Roxithromycin
8%
Side Effect
13%
Venous Thromboembolism
17%
Medicine and Dentistry
Adverse Event
8%
Alcohol Consumption
8%
All Cause Mortality
7%
Antibiotic Therapy
5%
Antibiotics
10%
Antibody Response
8%
Antidepressant
7%
Asthma
15%
Asthma Exacerbation
8%
Bronchiectasis
17%
Chronic Lung Disease
8%
Chronic Obstructive Pulmonary Disease
49%
Cohort Analysis
40%
Community-Acquired Pneumonia
10%
Corticosteroid
20%
COVID-19
20%
COVID-19 Vaccination
8%
Depression
8%
Genetic Analysis
8%
Hazard Ratio
6%
Inhalation
8%
Inhalation Device
8%
Medicine
5%
Mental Hospital
5%
Montelukast
8%
Outpatient
22%
Population
8%
Proportional Hazards Model
7%
Psoriasis
8%
Receptor Binding
6%
Retrospective Cohort Study
8%
Side Effect
9%
Social Distancing
26%
Venous Thromboembolism
17%
